Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| EP-155 | Human | Integrin α 4 β 7 : MAdCAM-1 [Biotinylated] Inhibitor Screening ELISA Kit | |||
| IT7-H52W4 | Human | Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free (MALS & SPR verified) |  |
|
|
Anti-Human Integrin α 4 β 7 MAb, Human IgG1 (ADCC Disable) captured on Protein A Chip can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (IT7-H52W4) with an affinity constant of 1.37 nM as determined in a SPR assay (Biacore 8K) (QC tested).
The purity of Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) is more than 85% and the molecular weight of this protein is around 210-250 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | 安吉优, Entyvio | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals U.S.A. Inc | 2014-05-20 | Colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Urogenital Neoplasms; Colitis, Ulcerative; Pediatric ulcerative colitis; Celiac Disease; Cholangitis, Sclerosing; Solid tumours; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); HIV Infections | Details |
| Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Crohn Disease; Multiple Sclerosis | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Multiple Sclerosis; Crohn Disease | Biogen Idec | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease | Details |
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | 安吉优, Entyvio | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals U.S.A. Inc | 2014-05-20 | Colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Urogenital Neoplasms; Colitis, Ulcerative; Pediatric ulcerative colitis; Celiac Disease; Cholangitis, Sclerosing; Solid tumours; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); HIV Infections | Details |
| Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Crohn Disease; Multiple Sclerosis | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Multiple Sclerosis; Crohn Disease | Biogen Idec | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Etrolizumab | PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 | Phase 3 Clinical | Genentech Inc | Colitis, Ulcerative; Crohn Disease | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Pouchitis; Colitis, Ulcerative; Crohn Disease | Details |
| MORF-057 | MORF-057 | Phase 2 Clinical | Morphic Therapeutic Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
| PN-10943 | PN-10943-A; PN-10943; PN-943 | Phase 2 Clinical | Protagonist Therapeutics Inc | Colitis, Ulcerative | Details |
| GS-1427 | GS-1427 | Phase 2 Clinical | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details | |
| ABBV-382 | Phase 2 Clinical | Abbvie Inc | HIV Infections | Details | |
| PTG-100 | PTG-100 | Phase 1 Clinical | Protagonist Therapeutics Inc | Celiac Disease; Colitis, Ulcerative | Details |
| Etrolizumab | PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 | Phase 3 Clinical | Genentech Inc | Colitis, Ulcerative; Crohn Disease | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Pouchitis; Colitis, Ulcerative; Crohn Disease | Details |
| MORF-057 | MORF-057 | Phase 2 Clinical | Morphic Therapeutic Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
| PN-10943 | PN-10943-A; PN-10943; PN-943 | Phase 2 Clinical | Protagonist Therapeutics Inc | Colitis, Ulcerative | Details |
| GS-1427 | GS-1427 | Phase 2 Clinical | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details | |
| ABBV-382 | Phase 2 Clinical | Abbvie Inc | HIV Infections | Details | |
| PTG-100 | PTG-100 | Phase 1 Clinical | Protagonist Therapeutics Inc | Celiac Disease; Colitis, Ulcerative | Details |
This web search service is supported by Google Inc.
A-Z
